4//SEC Filing
Bhat Laxminarayan 4
Accession 0001437749-25-004220
CIK 0001742927other
Filed
Feb 17, 7:00 PM ET
Accepted
Feb 18, 4:30 PM ET
Size
8.9 KB
Accession
0001437749-25-004220
Insider Transaction Report
Form 4
Bhat Laxminarayan
DirectorPresident and CEO10% Owner
Transactions
- Award
Stock Option (right to buy)
2025-02-13+519,000→ 519,000 totalExercise: $1.80Exp: 2035-02-12→ Common Stock, par value $0.0001 per share (519,000 underlying) - Award
Stock Option (right to buy)
2025-02-13+181,500→ 181,500 total(indirect: By Spouse)Exercise: $1.80Exp: 2035-02-12→ Common Stock, par value $0.0001 per share (181,500 underlying)
Footnotes (2)
- [F1]This option award was made on February 13, 2025 (the "Grant Date") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The option provides for vesting as follows: (i) 216,125 of the shares subject to the option are immediately vested on the Grant Date, (ii) 237,882 shares subject to the option will vest in equal installments on the last day of each month from March 2025 to December 2026, and (iii) 64,993 shares subject to the option will vest in equal installments on the last day of each month from January 2027 to December 2027. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan.
- [F2]This option award was made on the Grant Date in accordance with the terms of the 2020 Plan. The option provides for vesting as follows: (i) 75,625 of the shares subject to the option are immediately vested on the Grant Date, (ii) 83,195 shares subject to the option will vest in equal installments on the last day of each month from March 2025 to December 2026, and (iii) 22,680 shares subject to the option will vest in equal installments on the last day of each month from January 2027 to December 2027. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan.
Documents
Issuer
REVIVA PHARMACEUTICALS HOLDINGS, INC.
CIK 0001742927
Entity typeother
Related Parties
1- filerCIK 0001818245
Filing Metadata
- Form type
- 4
- Filed
- Feb 17, 7:00 PM ET
- Accepted
- Feb 18, 4:30 PM ET
- Size
- 8.9 KB